Naramig (Naratriptan Hydrochloride)

Naratriptan is a Triptan medication used in the migraine pathway to provide rapid relief of headache symptoms.

• Migraine: aborts acute migraine attacks and reduces headache intensity.
• Migraine with aura: alleviates pain and associated neurological symptoms during an attack.
• Migraine-associated nausea: helps lessen nausea when taken early in the episode.

• Naratriptan Hydrochloride acts as a selective agonist at serotonin 5‑HT1B and 5‑HT1D receptors located on cranial blood vessels and trigeminal nerve endings. Activation of these receptors induces vasoconstriction of intracranial arteries and inhibits the release of pro‑inflammatory neuropeptides, thereby interrupting the cascade that generates migraine pain. The drug’s high affinity for these receptor subtypes ensures a focused therapeutic effect with minimal peripheral activity.

Commonly reported adverse reactions to naratriptan are generally mild and transient, while rare events may be serious and require medical attention.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Fatigue: feeling unusually tired or weak.
• Nausea: mild stomach upset or urge to vomit.
• Dry mouth: reduced salivation causing throat discomfort.
• Paresthesia: tingling or numbness in extremities.
• Neck stiffness: mild muscular tension in the neck region.

Serious or Rare Side Effects

• Chest pain: discomfort that may indicate cardiac involvement.
• Hypertension: sudden increase in blood pressure.
• Serotonin syndrome: agitation, hyperthermia, and muscle rigidity when combined with serotonergic agents.
• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Coronary vasospasm: constriction of heart arteries causing ischemia.
• Arrhythmia: irregular heart rhythm requiring urgent care.

Before prescribing naratriptan, clinicians should evaluate patient history and consider specific safety measures.

• Assess cardiovascular risk: review history of coronary artery disease, angina, or stroke before use.
• Avoid concomitant ergot drugs: combined vasoconstriction may lead to severe vascular events.
• Monitor serotonergic therapy: use caution with SSRIs, SNRIs, or MAO inhibitors to prevent serotonin syndrome.
• Caution in uncontrolled hypertension: elevated blood pressure can be exacerbated by the drug.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and heat.

Naratriptan can interact with several medication classes; understanding the level of interaction helps guide safe co‑administration.

Major Interactions (Avoid)

• Ergot derivatives: combined vasoconstriction may cause serious vascular complications.
• Monoamine oxidase inhibitors (MAOIs): increased risk of serotonin syndrome when used together.
• SSRIs and SNRIs: potential for serotonin syndrome, especially at high doses.

Moderate Interactions (Monitor Closely)

• Other triptans: additive vasoconstrictive effect may increase cardiovascular risk.
• Antihypertensive agents: naratriptan may enhance blood pressure‑lowering effects.
• CYP1A2 inhibitors (e.g., fluvoxamine): may raise naratriptan plasma concentrations.